Overview

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

Status:
Not yet recruiting

Trial end date:
2027-08-01

Target enrollment:

Participant gender:

Summary

This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).

Phase:

Phase 3

Details

Lead Sponsor:

Daiichi Sankyo, Inc.

Collaborators:

AstraZeneca
Merck Sharp & Dohme LLC

Treatments:

Carboplatin
Cisplatin
Pembrolizumab
Pemetrexed